Floatz logo

Montanide Isa-51

Mixed Glioma

Roswell Park Cancer InstitutePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Mixed Glioma cohort.

Asset / SponsorPhaseRating
RITONAVIR
Case Comprehensive Cancer Center
Phase 2CCC
Inno-206
Washington University School of Medicine
Phase 2CCC
ETOPOSIDE
Washington University School of Medicine
Phase 2CCC
Lopinavir
Case Comprehensive Cancer Center
Phase 2CCC
FLUTICASONE
Roswell Park Cancer Institute
Phase 1CC

View all 11 →

Same molecule, other indications

Montanide Isa-51 is also rated in:

MelanomaDormant
BB
Indicative ·
64 / 100
View asset →
Advanced Renal Cell CancerDormant
BB
Indicative ·
64 / 100
View asset →
Stage IV MelanomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →